Ranganathan Raghini, Janarthanan Krishnaveni, Rajasekaran Senthilkumar
Department of Gastroenterology, PSG Institute of Medical Sciences and Research, Coimbatore - 641004, Tamil Nadu, India.
J Clin Exp Hepatol. 2012 Mar;2(1):86-7. doi: 10.1016/S0973-6883(12)60089-9. Epub 2012 Apr 12.
A 16-year-old female was treated with pegylated-interferon (PEG-IFN) alfa (a)-2b and ribavirin combination therapy for chronic hepatitis C virus (HCV) infection. She attained rapid virological response. She presented with diabetic ketoacidosis after 41 weeks of therapy. Anti-glutamic acid decarboxylase antibodies and islet cell antibodies were negative. Her fasting serum C-peptide level was <0.1 ng/mL, and the treatment course was completed. This case underlines the importance of periodic plasma glucose monitoring in patients during and after PEG-IFN and ribavirin therapy.
一名16岁女性接受聚乙二醇化干扰素（PEG-IFN）α-2b和利巴韦林联合治疗慢性丙型肝炎病毒（HCV）感染。她获得了快速病毒学应答。在治疗41周后，她出现了糖尿病酮症酸中毒。抗谷氨酸脱羧酶抗体和胰岛细胞抗体均为阴性。她的空腹血清C肽水平<0.1 ng/mL，治疗疗程完成。该病例强调了在接受PEG-IFN和利巴韦林治疗期间及之后对患者进行定期血糖监测的重要性。
